Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma
Induction Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma A Prospective Evaluation in Patients With Locally Advanced Pancreas Cancer
Sponsor: David A. Clump, MD, PhD
This PHASE2 trial investigates Pancreatic Cancer and is currently completed. David A. Clump, MD, PhD leads this study, which shows 12 recorded versions since 2011 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE2
-
May 2021 — Apr 2022 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2021 — May 2021 [monthly]
Active Not Recruiting PHASE2
▶ Show 7 earlier versions
-
Feb 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Feb 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE2
-
Sep 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE2
-
Aug 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Jul 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- David A. Clump, MD, PhD
For direct contact, visit the study record on ClinicalTrials.gov .